Medication info
Lirif Capsule 75 mg (Pregabalin)

Lirif Capsule 75 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Poonglim Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201802164 · Approved 2018.05.24 · Insurance code 649001770

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial seizures in epilepsy, and treatment of fibromyalgia
Who uses it
Adults · Children
Adult dosage
Administer the total daily dose of pregabalin in 2 divided doses, orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. For women, multiply the result obtained using the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a Starting dose (mg/day) / Maximum dose (mg/day) / Administration method ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Additional dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under Administration method. b: Additional dose refers to a supplemental dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 ~ 17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Poonglim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial seizures in epilepsy, and treatment of fibromyalgia

  • Peripheral and central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures in epilepsy, whether accompanied by secondary generalization or not. Additionally, it is effective in the treatment of fibromyalgia. By managing various pain and seizure symptoms associated with major neurological disorders, it improves the quality of life for patients.

Dosage and Administration

Adult dosage

Administer the total daily dose of pregabalin in 2 divided doses, orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See “5. Patients with Renal Impairment.”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See “4. Discontinuation of Treatment.”) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily; however, there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Since its clearance is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined by the following formula. For women, multiply the result obtained using the above equation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an additional supplemental dose should be administered promptly after every 4 hours of hemodialysis. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a Starting dose (mg/day) / Maximum dose (mg/day) / Administration method ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Additional dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under Administration method. b: Additional dose refers to a supplemental dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years: Administration is not recommended because there are insufficient safety and efficacy data. Adolescents aged 12 ~ 17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may lead to suicidal thoughts, suicidal behavior, and symptoms of depression during use, so both patients and caregivers should closely monitor for these changes. Patients with hypersensitivity to this drug should not use it. Diabetic patients should be cautious as weight gain after taking this medication may require adjustment of antidiabetic medication doses. If swelling, particularly around the face or mouth occurs during treatment, stop taking the medication immediately and consult a healthcare professional. Elderly individuals should be particularly cautious when starting this medication as it may cause dizziness or drowsiness, increasing the risk of falls or injuries. Some patients may experience blurred vision or changes in vision after taking this medication; if any abnormal symptoms occur, inform a healthcare professional. Abruptly discontinuing this medication may cause withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be gradually reduced according to a doctor's instructions. Patients with a history of drug abuse or mental illness should be closely monitored due to the risk of misuse or dependence on this medication. Patients with impaired kidney function should have their dose adjusted, and those with severe heart disease should use it cautiously. Taking this medication with opioid analgesics may increase central nervous system depressant effects, posing risks such as respiratory depression. Due to the risk of fetal malformation in early pregnancy, it is advisable for pregnant women to avoid taking this medication, and fertile women should use effective contraception. Breastfeeding women should consider discontinuing breastfeeding or the medication, as it may be transmitted through breast milk and affect the baby. Activities requiring concentration, such as driving or operating machinery, should be avoided until dizziness or drowsiness subsides after taking this medication. In cases of overdose, severe symptoms such as confusion, drowsiness, and seizures may occur, necessitating immediate medical treatment. This medication should be stored out of reach of children and should not be transferred to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial edema
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 179 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • sadness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • respiratory function deterioration
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasm
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle stiffness
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling intoxicated
  • paresthesia
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • increased serum creatinine
  • decreased white blood cell count
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • anxiety
  • mood swings
  • emotional lability
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to restrain
  • apathy
  • ataxia
  • motor coordination abnormalities
  • balance disorders
  • amnesia
  • attention disorder
  • memory impairment
  • tremor
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • tonic spasms
  • decreased reflexes
  • motor abnormalities
  • psychomotor agitation
  • position-induced dizziness
  • hyperalgesia
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • motor retardation
  • olfactory disturbance
  • taste loss
  • writing impairment
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • exacerbation of cramps
  • shock
  • symptoms resembling anaphylaxis
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. Additionally, it is important to store it at room temperature between 15 to 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.